ArticleEuropean journal of nuclear medicine and molecular imaging2022
Comparing the clinical performance and cost efficacy of [
Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Assessing Value for Money in Theranostic Nuclear Medicine: A Systematic Review.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Pooled it
- Comparison ofProstate cancer and prostatic diseases · 2024Pooled it
- The diagnostic accuracy of radiolabeled PSMA-ligand PET for tumour staging in newly diagnosed prostate cancer patients compared to histopathology: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2023Pooled it
- Economic Evaluations of Imaging Biomarker-Driven Companion Diagnostics for Cancer: A Systematic Review.Applied health economics and health policy · 2023Pooled it
- Chrónos and Káiros in theragnostics: re-assessing time toxicity in final-line radiopharmaceutical treatments.European journal of nuclear medicine and molecular imaging · 2026Article
- Evaluating [Journal of market access & health policy · 2026Article
- Detection Rates of PSMA-PET Radiopharmaceuticals in Recurrent Prostate Cancer: A Systematic Review.Diagnostics (Basel, Switzerland) · 2025Review
- The Role of 18F PSMA-1007 PET/CT in the Staging and Detection of Recurrence of Prostate Cancer, A Scoping Review.Cancers · 2025Review
- Comparison of early and standardAnnals of nuclear medicine · 2025Article
- Comparative dosimetric evaluation of 68Ga-PSMA and 18F-Choline PET/CT imaging in prostate cancer: implications for radiation safety and SUVmax correlation.Frontiers in nuclear medicine · 2025Article
- Update on PSMA-based Prostate Cancer Imaging.Seminars in nuclear medicine · 2024Review
- Article
- Head-to-Head Comparison of [Cancers · 2024Article
- Covariate dependent Markov chains constructed with gradient boost modeling can effectively generate long-term predictions of obesity trends.BMC research notes · 2023Article
- Comparison between [International journal of molecular sciences · 2023Article
- Article
- The Role of [Cancers · 2022Review
- Assessment of malignancy and PSMA expression of uncertain bone foci in [European journal of nuclear medicine and molecular imaging · 2022Article
- Article
- Feasibility of late acquisition [68Ga]Ga-PSMA-11 PET/CT using a long axial field-of-view PET/CT scanner for the diagnosis of recurrent prostate cancer-first clinical experiences.European journal of nuclear medicine and molecular imaging · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeAmongst others, [
methodsTwo hundred and forty-four patients undergoing PSMA PET/CT for rPC were retrospectively analysed for this study (one hundred and twenty two with each radiopharmaceutical) to generate rates of PET positivity, negativity and unclear findings. Patients underwent follow-up to determine the rate of additional examinations and to confirm PET findings. A Markov chain decision analysis was implemented to model clinical decision-making processes and to analyse clinical performance of the two tracers. We determine their clinical cost efficacies using cost data from several countries where both radiotracers are in routine use.
resultsThe PET positivity rate was non-significantly higher for [
conclusionThe analysis reveals a non-significantly higher PET positivity rate for [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.